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E piretinal membrane (ERM) is a common retinal disease characterized by cellular proliferation and 
metaplasia that lead to the formation of a pathological 
fibrocellular membrane immediately superjacent to the 
inner retinal surface (Figs. 1A and 1B).  The terms 
epimacular membrane,  macular pucker,  cellophane 
maculopathy,  and preretinal macular fibrosis have been 
used to describe this condition [1-7].
Of late,  technology related to ERM surgery,  includ-
ing imaging analyses and surgical devices,  has made 
rapid progress.  In this review,  we provide an overview 
of and recent insights into the surgical management of 
ERM.
Epidemiology and Pathogenesis of ERM
The vast majority of ERM cases are considered idio-
pathic and unassociated with other systemic or ocular 
diseases.  They are found most frequently after 50 years 
of age,  and several large clinical studies have reported a 
clinical prevalence of 7% to 11.8% [8 , 9].  Most ERMs 
are asymptomatic,  with many being extrafoveal in loca-
tion.  There appears to be no significant gender predi-
lection,  and ERM is bilateral in 20-30% of cases.  
Posterior vitreous detachment (PVD) is present in up to 
90% of clinically significant ERMs,  with spontaneous 
posterior hyaloid separation believed to be the causative 
factor.  The Blue Mountains Eye Study reported second 
eye involvement over a 5-year period in 13.5% of 
patients [10].
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Epiretinal membrane (ERM) is a common retinal disease characterized by cellular proliferation and metaplasia 
that lead to the formation of a pathological fibrocellular membrane immediately superjacent to the inner retinal 
surface.  The vast majority of ERMs are considered idiopathic.  However,  ERM formation can result from vari-
ous primary intraocular diseases,  including retinal breaks and detachment,  retinal vascular diseases,  and vit-
reoretinal inflammatory conditions.  Although ERMs are generally asymptomatic or cause mild metamorphop-
sia and/or a modest decrease in visual acuity,  some can cause severe macular distortion and macular edema,  
resulting in significantly impaired function.  Surgical removal of ERM is the only treatment,  and improvements 
in vitrectomy systems have enabled less invasive treatment.  However,  there are currently no standardized crite-
ria for ERM surgery,  and the indications for surgery are determined from the patient’s subjective symptoms.  
Another problem with ERM surgery is that not all patients show satisfactory postoperative recovery of visual 
function.  Thus,  further research is needed to determine the criteria for ERM surgery and methods to improve 
the postoperative prognosis.
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With regard to the mechanism underlying idiopathic 
ERM formation,  there are several possible theories.  
Some researchers have suggested that defects in the 
internal limiting membrane (ILM) created by PVD 
allow retinal glial cells (Müller cells and astrocytes) to 
migrate to the inner surface of the retina,  where they 
form an idiopathic ERM [11 , 12].  Others suggest that,  
as a result of vitreoschisis and vitreoretinal traction 
caused by anomalous PVD,  hyalocytes in the cortical 
vitreous remnants in the macular region are stimulated 
by various cytokines,  such as basic fibroblast growth 
factor and nerve growth factor,  after which they prolif-
erate and differentiate into myofibroblasts,  leading to 
idiopathic ERM formation [13-16].  However,  the 
pathogenesis of ERM is not fully understood.
Nonidiopathic (secondary) ERMs have been associ-
ated with several vitreoretinal diseases,  including reti-
nal vascular diseases (e.g.,  diabetic and hypertensive 
retinopathy,  venous occlusive disease,  angiomas,  tel-
angiectasis,  etc.),  vitreoretinal inflammatory conditions 
(e.g.,  infectious or noninfectious uveitis),  postoperative 
and post-traumatic states,  inherited and congenital 
posterior segment anomalies and syndromes,  intraocu-
lar tumors,  and retinal breaks and detachment [17-41].
The pathogenesis of secondary ERMs differs from 
that of idiopathic ERMs because of the central role 
played by inflammation,  which induces cellular prolif-
eration and transdifferentiation to promote ERM for-
mation and contraction.  This mechanism is evidenced 
by an increase in the expression of cytokines such as 
interleukin-6 and 8 and monocyte chemoattractant 
protein-1 [42].  These cytokines are known to support 
inflammatory cells identified in secondary ERMs 
[43 , 44].
ERMs that occur following retinal breaks and 
detachment are thought to have a pathogenic mecha-
nism in addition to inflammation; RPE cells gain access 
to the vitreous cavity through the retinal break and set-
tle on the macular surface,  subsequently developing 
into a membrane [45].  These membranes are architec-
turally enhanced by the presence of fibroblasts and mac-
rophages,  which are stimulated in part by the inflam-
mation associated with vitreous hemorrhage and/or 
surgical repair.
Visual Function in ERM
ERMs are usually asymptomatic or cause mild 
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Fig. 1　 Epiretinal membrane (ERM) 
with retinal folds.  A,  Representative 
color photograph of ERM.  The arrows 
indicate the area of ERM.  The dotted 
arrow indicates the scan direction of the 
B-scan optical coherence tomography 
(OCT) image shown in (B).  The dotted 
square shows the scan area of the en 
face OCT images shown in (C) and 
(D); B,  Horizontal B-scan OCT image.  
The hyperreflective line (arrows) on the 
retinal surface shows ERM.  The foveal 
pit is absent (arrowhead),  and several 
cysts are present in the retinal layers 
(asterisks); C,  En face OCT image at 
the internal limiting membrane (ILM) 
level.  ERM can be seen as a hyperre-
flective membrane-like structure (aster-
isk).  The arrows indicate the retinal 
folds caused by traction from ERM; D,  
En face OCT image obtained 30 µm 
below ILM.  The black linear structures 
(arrows) indicate the retinal folds.
symptoms of metamorphopsia and/or a modest 
decrease in visual acuity.  Among patients with idio-
pathic ERMs,  two-thirds exhibit a visual acuity of 
20/30 or better,  while 85% display a visual acuity of 
20/70 or better [7 , 46].  A visual acuity of 20/200 or 
lower may be observed in a small number of patients 
(approximately 5%) [47-49].  A few of these mem-
branes can cause macular distortion and edema to the 
extent that clinicians recommend their removal via pars 
plana vitrectomy.
One of the most common symptoms in ERM 
patients is metamorphopsia,  which is a subjective 
symptom characterized by distortion of viewed objects.  
In patients with ERM,  metamorphopsia is thought to 
result from the displacement of photoreceptors due to 
retinal traction and/or visual cortex reorganization as 
well as perceptual adjustment in response to disrupted 
sensory input from the retina [50-56].  Metamorphopsia 
is quantitatively evaluated using M-CHARTS (Inami 
Co.,  Tokyo).  The severity of distorted vision in normal 
eyes is 0 in both the vertical and horizontal directions.  
In general,  difficulties in daily life start to occur when 
the severity of distorted vision exceeds 0.5,  and ERM 
surgery might be indicated at this point [57].
Imaging Analyses of ERM
Optical coherence tomography (OCT) plays an 
important role in the clinical assessment of eyes with 
ERMs.  OCT can detect ERMs and can also assist in 
topographic localization,  identification of vitreoretinal 
relationships (such as vitreomacular traction syndrome),  
detection of lamellar or full-thickness macular holes and 
retinal folds,  and quantitation of macular thickness and 
macular volume (Figs . 1B-1D) [58].  In addition to its 
value in clinical characterization,  OCT has therapeutic 
value in preoperative planning.  The co-existence of a 
macular hole,  the presence of a bilaminar ERM,  or 
knowledge of substantive macular edema may lead the 
surgeon to modify his or her approach.  OCT also 
shows considerable prognostic value in terms of coun-
seling patients regarding the visual potential of the 
affected eye.  Finally,  it can assist in postoperative man-
agement via assessments of the macular thickness and 
membrane regrowth.
Treatment of ERM 
Surgical excision is the only available treatment 
option for ERM.  The aim of surgical intervention is to 
improve traction-induced visual disturbance via 
removal of ERM,  which relieves the macular traction.  
In recent years,  the increased resolution of OCT has 
enabled the early detection of asymptomatic ERMs [58-
60].  However,  no objective or quantitative criteria for 
indicating surgical removal of ERM have been estab-
lished.  Therefore,  it is essential to conduct a thorough 
risk/benefit analysis and carefully judge whether sur-
gery is indicated based on the results of subjective visual 
function tests as well as the patient’s lifestyle and envi-
ronment.
Surgical Procedure
Surgical setting. In recent years,  several 
advancements have facilitated safe and relatively fast 
vitrectomy; these include the availability of better 
microincision vitrectomy surgery (MIVS) systems,  
development of small-gauge forceps and chandelier 
illumination,  improvements in light-emitting diodes 
and other light sources,  and availability of microscope 
systems with wide fields of vision.  When performed 
using the new MIVS system,  vitrectomy uses three or 
four ports.  The size of the vitrectomy device can be 
either 20-,  23-,  25-,  or 27-gauge.  The 25-gauge system 
is the principal vitrectomy system in international use,  
although the 27-gauge system is gradually seeing wider 
adoption.  In recent years,  digitally assisted vitrectomy 
surgery has become available,  and it has become possi-
ble to perform macular surgery,  including surgery for 
ERM,  at higher magnifications and lower illumination 
intensities.  If cataracts are clinically present before 
ERM surgery and/or the patient is aged over 50 years 
and his/her cataracts are expected to progress after sur-
gery,  the cataract surgery system should be prepared 
such that cataract surgery and intraocular lens (IOL) 
implantation can be performed simultaneously with 
vitrectomy.
Visualization of vitreous, induction of posterior 
vitreous detachment, and core and peripheral vitrec-
tomy. After core vitrectomy,  the vitreous body is 
visualized by steroid particles (triamcinolone aceton-
ide) to confirm the occurrence of PVD [61 , 62].  PVD 
occurs spontaneously in approximately 70% of cases of 
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ERM [63].  However,  when it has not occurred,  it is 
induced by aspiration of the vitreous body.  The adhe-
sion between the vitreous body and ERM is sometimes 
extremely strong; therefore,  when the vitreous body is 
aspirated,  care must be taken to avoid macular damage 
from excessive traction.  After PVD,  core and periph-
eral vitrectomy is performed.  Any vitreous body 
remaining in the area surrounding the trocar can lead to 
an increased risk of retinal tears due to traction from the 
vitreous body when instruments are inserted or 
extracted.  Therefore,  it is safer to excise the part of the 
vitreous body surrounding the trocar.  In phakic eyes,  
the lens should not be allowed to come in contact with 
the vitreous cutter.  The combined use of chandelier 
illumination and a wide-angle viewing system can facil-
itate safe and efficient surgery with a wide field of 
vision.
Visualization and peeling of ERM. It is generally 
difficult to distinguish the boundary between ERM and 
the retina; therefore,  triamcinolone acetonide and vital 
dyes are used to enhance ERM visualization so that safe 
and complete ERM peeling can be achieved.  Commonly 
used vital dyes include trypan blue,  indocyanine green 
(ICG),  and brilliant blue G (BBG) [64-72].  
Triamcinolone acetonide adheres to ERM but not to 
ILM (Figs. 2A and 2B),  whereas trypan blue passes 
through cell membranes and stains the cells,  with 
greater affinity for ERM than for ILM.  Therefore,  use of 
these 2 visualizing agents enables positive visualization 
of ERM.  In contrast,  ICG and BBG stain ILM but not 
ERM,  enabling negative staining of ERM.  Appropriate 
use of these agents based on an understanding of their 
properties allows for effective visualization of the rele-
vant structures during ERM surgery.  Removal of ILM,  
the scaffold for myofibroblast proliferation,  enables 
complete removal of ERM and has been suggested to 
reduce the risk of ERM recurrence [73-77].  If ILM 
peeling is performed at the same time as ERM surgery,  
retinal staining with ICG and BBG should be performed 
multiple times before and after ERM and ILM peeling to 
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Fig. 2　 Images captured during epiret-
inal membrane (ERM) surgery.  A,  ERM 
is visualized with triamcinolone aceton-
ide (arrows); B,  ERM visualized with 
triamcinolone acetonide (arrows) is 
peeled with end-grabbing forceps (aster-
isk).  The arrowheads indicate the edge 
of the peeled ERM; C,  The internal 
limiting membrane (ILM) visualized with 
brilliant blue G (BBG) (black arrow) 
around the fovea (white arrow) is peeled 
with end-grabbing forceps (asterisk).  
The arrowheads indicate the edge of the 
peeled ILM; D,  The region without BBG 
staining (dotted area) is the ILM-peeled 
area.  The arrow indicates the fovea.
enable timely assessment of the presence of any residual 
ERM or ILM (Figs. 2C and 2D) [78-80].  Although it 
was recently reported that trypan blue and BBG show 
lower cytotoxicity than does ICG,  any of these staining 
agents can be cytotoxic if used at too high a concentra-
tion [80-82].  Thus,  the appropriate concentrations 
must be used,  and the agents must be sufficiently 
washed out after use.
If the boundary between ERM and the retina is clear,  
ERM peeling can be performed by directly grasping the 
ERM margin using end-grabbing forceps.  Initiation of 
ERM peeling in the space between ERM and the retina 
reduces the risk of retinal damage during surgery.  The 
site at which ERM peeling is initiated can be deter-
mined using either preoperative OCT or a surgical 
microscope in combination with integrated intraopera-
tive OCT.  If the boundary between ERM and the retina 
as well as any space between ERM and the retina is not 
clear,  ERM peeling should be preferably initiated at the 
temporal inferior area of the macula,  not in the area of 
the papillomacular bundle or any site in close proximity 
to the macula; this avoids damage to the central and 
lower parts of the field of vision.
The appropriate area of ERM peeling has not been 
established.  Hirano et al.  reported that ERM and ILM 
peeling completely resolved retinal traction caused by 
ERM,  and that the traction outside the parafoveal area,  
a 3-mm-diameter circle centered at the fovea,  did not 
affect the postoperative improvement in visual function 
[58].  Kanzaki et al.  reported that ERM formation did 
not affect visual function when the area of ILM peeling 
was larger than the parafoveal area [83].  In consider-
ation of these reports,  a 3-mm-diameter circle centered 
at the fovea may be the minimum area required for 
ERM and ILM peeling.
Complications of Surgery
Posterior retinal breaks, macular hole, and retinal 
hemorrhage. When peeling ERM and/or ILM,  reti-
nal traction can cause posterior retinal breaks,  macular 
holes,  and retinal hemorrhages.  For a minor posterior 
retinal break,  gas tamponade with subsequent monitor-
ing for progression is sufficient.  In contrast,  if the 
retinal break is distant from the macula,  or if a major 
retinal break is likely to cause postoperative retinal 
detachment,  it is necessary to perform laser treatment 
around the break,  followed by gas tamponade.  If a 
macular hole forms,  ILM peeling and gas tamponade 
are performed.  Retinal hemorrhage is generally self- 
limiting and does not require treatment; however,  it 
can be stopped if necessary by increasing the irrigation 
pressure or applying diathermy.
Intraoperative lens damage. Devices that are 
inserted into phakic eyes,  including trocars,  vitreous 
cutters,  light pipes,  and end-grabbing forceps,  rarely 
come in contact with the lens and damage it.  In case 
these devices touch the lens,  ERM peeling is still feasi-
ble if the damage to the lens is minor.  However,  lensec-
tomy is required if the damage results in reduced retinal 
visibility.  Depending on the condition of the lens cap-
sule,  IOL can be simultaneously implanted.  If the lens 
capsule is severely damaged,  IOL is implanted with 
sutured fixation or sutureless intrascleral fixation,  gen-
erally as a secondary treatment.  Postoperative progres-
sion of cataracts frequently occurs when surgery is 
completed in the phakic state.  Secondary cataract sur-
gery is performed in these cases,  but these surgeries are 
somewhat difficult because of a higher probability of 
posterior capsule rupture.
Postoperative cataracts. Postoperative nuclear 
sclerotic cataracts develop in 10-70% of phakic eyes after 
completion of lens-sparing surgery [73 , 84-88].  The 
probability of this complication occurring in an earlier 
postoperative phase is higher in older patients; thus,  
patients aged over 50 and/or those with pre-existing 
nuclear sclerosis are treated with phacoemulsification 
and IOL implantation simultaneously with ERM sur-
gery [89 , 90].  In most cases,  phacoemulsification is 
performed first,  followed by vitrectomy.  IOL implanta-
tion is performed before or after vitrectomy depending 
on the surgeon’s preference.
Peripheral retinal tear and postoperative retinal 
detachment. Peripheral retinal tears are found in up 
to 6% of cases [63 , 73 , 86 , 87 , 91-94],  but the frequency 
of this complication appears to be lower when MIVS is 
applied [95 , 96].  Peripheral retinal tears often develop 
in association with surgical equipment insertion,  which 
can cause traction from the vitreous body in the vitre-
ous base.  Therefore,  peripheral retinal tears can be 
prevented by excising the vitreous body surrounding 
the trocar.  In patients who show lattice degeneration 
and strong adherence between the vitreous body and 
retina,  excessive aspiration of the vitreous body during 
PVD induction should be avoided for the prevention of 
peripheral retinal tears.  A search for retinal tears 
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should be carefully performed using a wide-angle view-
ing system and scleral indentation to ensure that no 
peripheral retinal tears are overlooked.  If peripheral 
retinal tears are found,  the vitreous body surrounding 
them should be shaved; in addition,  laser photocoagu-
lation or transscleral cryotherapy should be applied to 
the retinal tears.  Fluid–air or fluid–gas exchange can 
then be performed to complete the surgery.  Posto-
perative retinal detachment occurs in up to 14% of 
patients undergoing vitrectomy surgery,  and this com-
plication is usually associated with overlooked periph-
eral tears or later contraction of the vitreous base 
[85 , 86 , 92 , 93 , 97].  If postoperative retinal detachment 
occurs,  retinal detachment repair surgery should be 
performed as soon as possible,  depending on the state 
of the retinal detachment.
Other complications associated with ERM peeling.
Other complications associated with ERM peeling have 
also been reported,  including endophthalmitis,  retinal 
phototoxicity,  choroidal neovascularization,  and visual 
field defects.  Acute-onset endophthalmitis is a serious 
complication with an incidence rate of 0.030-0.070% 
[98-100].  In general,  thorough sterilization of equip-
ment as well as the use of disposable items and topical 
antibiotics are encouraged.  Additionally,  an important 
practice to prevent endophthalmitis when performing 
MIVS is to suture the scleral incision site if the self-seal-
ing of the scleral incision is judged to be insufficient at 
the completion of surgery [101].
ERM recurrence. Recurrence of epiretinal tissue 
formation after vitrectomy is observed in less than 20% 
of patients and rarely has a significant effect on vision 
[73 , 76 , 86 , 87 , 92 , 102].  ERM recurrence is thought to 
be caused by the residual vitreous cortex and/or insuffi-
cient ERM removal.  Additionally,  the current body of 
evidence suggests that ILM provides a scaffold for ERM 
recurrence [102].  In their 2017 meta-analysis,  Chang et 
al.  reported that vitrectomy with ILM peeling is associ-
ated with lower rates of ERM recurrence [103],  
although the proportion of cases with vision-limiting 
recurrent ERM is small.  If ERM recurrence reduces 
visual function,  ERM peeling is repeated.
Controversies related to ILM peeling. There are 
several reasons that ILM peeling should be avoided.  
One is that ILM is the basal lamina connected to the end 
feet of the Muller cells; thus,  ILM peeling can cause 
mechanical damage to the retinal tissues,  which could 
potentially lead to dissociation of the nerve fiber layer 
and inner retinal dimpling.  Other reasons are that ILM 
peeling can affect Müller cell function,  and that the 
stains used to visualize ILM have cytotoxic effects [104-
110].
Several meta-analyses to investigate the safety and 
efficacy of ILM peeling have recently been published 
[103 , 111 , 112].  However,  it remains unclear whether 
ILM peeling should be routinely performed for patients 
with ERM; to clarify this point,  it will be necessary to 
monitor a larger number of patients for extended peri-
ods and conduct prospective randomized clinical trials.
Postoperative Changes in Visual Function
Visual acuity. In most patients,  the macular sur-
face architecture is greatly improved immediately after 
surgery,  although a short-term decrease in the visual 
acuity to below the preoperative level is not uncom-
mon.  While immediate and significant improvements 
in the visual acuity may occur,  it often takes 4 to 6 
weeks for the patient’s vision to return to the preopera-
tive level,  and subsequent improvement continues over 
the following 3 to 6 months.  It has been reported that 
60-90% of patients show a visual acuity improvement of 
two or more lines by 6 to 12 months after surgery 
[84 , 86 , 87 , 92 , 97 , 113-116].
Numerous studies have been conducted to elucidate 
the factors associated with visual acuity prognosis.  
Previously reported preoperative factors associated with 
better postoperative visual acuity include better preop-
erative visual acuity [113 , 114 , 117-122],  greater inner 
nuclear layer (INL) thickness [123],  greater photore-
ceptor outer segment length [121],  ellipsoid zone integ-
rity [113 , 118 , 119 , 124-126],  and lesser central foveal 
thickness [120 , 123 , 125 , 127].
Metamorphopsia. Metamorphopsia is alleviated 
by ERM peeling,  but it is not completely cured by the 
procedure,  probably because the photoreceptor cell 
arrangement does not revert to its exact original state 
following ERM peeling.  According to a report by 
Kinoshita et al.,  metamorphopsia is present at approxi-
mately 50% and 30% of the preoperative level at 3 
months and 1 year after surgery,  respectively [114].  In 
particular,  the INL thickness has been reported to be 
significantly associated with metamorphopsia,  with a 
thicker INL being associated with more severe meta-
morphopsia both preoperatively and postoperatively 
[128-130].
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A Peculiar Type of ERM: Lamellar Hole-
Associated Epiretinal Proliferation (LHEP)
LHEP is a membranous tissue seen on the surface of 
the retina and was first reported by Witkin et al.  [131].  
LHEP is mainly observed in patients with macular hole 
and degenerative lamellar macular hole (LMH),  which 
is a type of LMH that involves very little retinal traction 
in its pathology [59 , 132 , 133].  The term “LHEP” was 
coined by Pang et al.,  and the condition has also been 
termed “dense non-tractional ERM” and “atypical 
epiretinal tissue” [133-135].  Recently,  it was reported 
that the presence of LHEP is not exclusive to LMH 
[136],  and Hubschman et al.  proposed to delete the 
prefix “lamellar-hole associated” from LHEP and term 
the membrane “epiretinal proliferation” [137].  
However,  LHEP remains the best-known and most fre-
quently used term.
Unlike idiopathic ERMs,  LHEPs are yellow because 
of the presence of carotenoids [138].  In addition,  
LHEPs appear thick with moderate reflectivity in OCT 
[133],  whereas idiopathic ERMs are thin and highly 
reflective.  Although LHEPs are highly extensible and 
can be readily peeled off the retinal surface,  complete 
removal is difficult because they are closely associated 
with retinal tissue at the LMH and macular hole mar-
gins [134 , 135 , 139-141],  a feature not shared with idio-
pathic ERMs.
Histological studies have shown that LHEPs contain 
cells that are positive for specific markers of glial cells or 
hyalocytes.  These cells are therefore considered to be 
the major components of LHEPs [139 , 142-148].  On the 
other hand,  LHEPs do not stain with α-smooth muscle 
actin antibody,  suggesting that they do not have con-
tractile properties [139 , 146].
Treatment of degenerative LMH leads to challenges 
regarding the approach to LHEPs [132].  Until now,  
degenerative LMH has been treated by both ILM and 
LHEP removal.  However,  it has been reported that 
visual acuity improvements following surgery are insuf-
ficient,  and postoperative macular holes develop in 
16% of cases [134 , 149 , 150].  Recently,  Shiraga et al.  
proposed a new surgical technique to treat LHEP asso-
ciated with degenerative LMH,  wherein LHEP is 
embedded into the macular aperture such that it fills the 
retinal gap [140 , 151 , 152].  The same group reported 
postoperative improvements in the macular contour 
and visual acuity [140 , 151 , 152].  Similar to the 
inverted ILM flap technique,  the mechanism of action 
of the LHEP embedding technique is thought to be res-
toration of the macular structure by glial cells within 
LHEP [153 , 154].  Although the results thus far are 
promising,  further research on this treatment approach 
for degenerative LMH is necessary.
Conclusions
The efficacy of surgical removal of ERMs by vitrec-
tomy for improving visual function was first reported by 
Machemer in 1978 [155].  In the more than 40 years 
since,  progress in OCT technology and vitrectomy sys-
tems has resulted in detailed elucidation of the ERM 
pathology and enabled less invasive treatment.  
However,  clear criteria indicating surgery remain to be 
established,  and indications for surgery are,  therefore,  
still based on the patient’s subjective symptoms along 
with the physician’s judgment.  Another problem is that 
not all patients show satisfactory recovery of visual 
function after surgery.  Further research regarding the 
criteria for indicating ERM surgery and the factors 
associated with the visual prognosis is necessary.
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